Kura Oncology Inc. (NASDAQ:KURA) shares were up 4.7% on Tuesday . The stock traded as high as $5.45 and last traded at $5.38, with a volume of 141,664 shares. The stock had previously closed at $5.14.

Several research analysts have weighed in on KURA shares. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Tuesday, June 21st.

The stock’s market capitalization is $96.44 million. The company’s 50-day moving average price is $3.88 and its 200-day moving average price is $3.64.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.02. Analysts predict that Kura Oncology Inc. will post ($1.72) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.